A Study on Impact of Merger and Acquisition on Financial Performance of Agri-Food Companies by I. Gupta, T. V. Raman

Get full text

Shareholder’s reaction to Merger and acquisition announcement: evidence from india’s Manufacturing sector by I. Gupta, T. V. Raman

Get full text

"Evaluation of Trichomonas Vaginalis Isolates from Symptomatic and Asymptomatic Patients in Mouse Model" by Z Valadkhani, S Sharma, K Harjai, I Gupta, N Malla

Get full text

A cost analysis of deliveries conducted in various health care settings in a city of India by Hemant Tiwari, Kinnari I Gupta, Gneyaa S Bhatt, Sheetal Vyas

Get full text

P941: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH LENALIDOMIDE PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-6 ARM-A INTERIM... by H. Quach, M. Gironella, C. Lee, R. Popat, P. Cannell, R. S. Kasinathan, B. Chopra, R. Rogers, G. Ferron-Brady, S. Shafi-Harji, N. Patel, J. Opalinska, I. Gupta, B. Augustson

Get full text

Impact of prolonged dose delays on response with belantamab mafodotin (belamaf; gsk2857916) treatment in dreamm-2 study: 13-month follow-up by A. Medaglia, A.D. Cohen, H.C. Lee, S. Trudel, A-O. Abdallah, N. Callander, E. Libby, L. Karlin, S. Lonial, L. Womersley, J. Baron, E. Lewis, K. Nungesser, I. Gupta, J. Opalinska

Get full text

P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY by A. Suvannasankha, N. Bahlis, S. Trudel, K. Weisel, C. Koenecke, A. Oriol, P. M. Voorhees, A. A. Alonso, N. S. Callander, M. V. Mateos Manteca, N. Reddy, S. Hakim, N. Patel, D. Williams, R. C. Jewell, X. Zhou, I. Gupta, A. K. Nooka

Get full text

P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL by A. Nooka, A. Cohen, H. Lee, A. Badros, A. Suvannasankha, N. Callander, A. Abdallah, S. Trudel, A. Chari, E. Libby, M. Chaudhry, M. Hultcrantz, K.M. Kortüm, P. Richardson, R. Popat, D. Sborov, S. Hakim, E. Lewis, B. Bhushan, B. Gorsh, I. Gupta, J. Opalinska, S. Lonial

Get full text

P14: DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN PLUS STANDARD OF CARE IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA by S Usmani, A Alonso, H Quach, Y Koh, A Guenther, CK Min, X Leleu, AO Abdallah, A Oriol, B Bessemer, M Garg, I Sandhu, K Weisel, E Ocio San Miguel, M Cavo, X Zhou, M Kaisermann, L Mis, D Williams, A Yeakey, G Ferron-Brady, D Figueroa, B Kremer, I Gupta, W Janowski

Get full text

Dreamm-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma (rrmm), including subgroups with renal impairment (ri) and high-risk (hr) cytogen... by S. Lonial, H.C. Lee, A. Badros, S. Trudel, A.K. Nooka, A. Chari, A-O. Abdallah, N.S. Callander, D.W. Sborov, A. Suvannasankha, K. Weisel, P.M. Voorhees, M. Hultcrantz, E.N. Libby, P.G. Richardson, P. Rodriguez Otero, B. Besemer, T. Facon, A. Hoos, J. Baron, T. Piontek, R.C. Jewell, E. Lewis, J. Opalinska, I. Gupta, A.D. Cohen, A. Medaglia

Get full text